This brochure provides an overview of the Sequential Intercept Model (SIM). The SIM is a strategic planning tool that helps communities better understand the gaps and resources they have in helping those with mental illness or substance use disorders who are in the criminal justice system.

This manual provides a starting place for jurisdictions looking to use data to better understand and improve the outcomes of people with mental and/or substance use disorders who come into contact with the criminal justice system.

This guide focuses on using medication-assisted treatment for opioid use disorder in jails and prisons and during the reentry process when justice -involved persons return to the community. It provides an overview of policies and evidence-based practices that reduce the risk of overdose and relapse.

This report provides evidence-based practices for screening and assessment of adults in the justice system with mental illness, substance use disorders, or both. It discusses the importance of instrument selection for screening and assessment and provides detailed descriptions of recommended instruments.

This brief provides guidance to state governments on increasing the availability of evidence-based medication-assisted treatment (MAT) in criminal justice (CJ) settings. By including the criminal justice system as a path to treatment, states may see an increase in access to and retention in treatment, and lower rates of overdoses, re-offending, and re-incarcerations. In this brief, states are provided an overview of the issue, the challenges to incorporating MAT, key considerations for establishing MAT in CJ settings, and existing standards/guidelines.

This guide provides information and practices that behavioral health providers can implement in their daily practice with patients or clients who are involved in the criminal justice system.

This guide highlights the use of medication-assisted treatment (MAT) for opioid use disorder in drug courts. It reviews effective medications, including methadone, buprenorphine, and naltrexone. The guide also provides strategies to increase the use of MAT in drug court programs.